TruaceTracing the truth around AITuesday, September 15, 2026
The Index

What the evidence says.What the public feels.

Ranks distinct AI gain and problem claims from the published record. Scores reward impact, independent source strength, scale, confidence, and recency.

1,419 results
Show filters and sorting

AI gains · 788

72
GainHealth· Stable· Evidence: Moderate (1 source)

In two Canadian diagnostic laboratories, AI-based PhenoMATRIX urine culture assessment enabled earlier availability of interpretable results and reduced time to result reporting by about 1.3 hours with automated PM+ release at a tertiary hospital and about 5.3 hours with earlier manual screening at a community lab.

By July 10 2026, a dual-center Canadian study reported before-and-after results for PhenoMATRIX, an AI-based software that provides continuous culture sorting and interpretation support for urine cultures on laboratory automation. Both a low-volume tertiary hospital and a high-volume community lab saw earlier availability of interpretable results, with measured TTRR changes of approximately 1.3 hours with PM+ automated release and approximately 5.3 hours with earlier manual review.

Impact 30%63
Evidence 25%95
Scale 20%35
Confidence 15%87
Recency 10%89

Updated Jul 20, 2026 · TRV-2026-0322

72
GainHealth· Stable· Evidence: Moderate (1 source)

Custom GPT models completed all QUIPS domain judgments and reduced data-extraction time from 30.4 to 5.7 minutes per study in rheumatology systematic reviews.

Researchers nested a two-part methodological study within two PROSPERO-registered reviews to test customized GPT models on complex rheumatology evidence synthesis. Fifteen SLE metabolomics studies were used to compare human and GPT data extraction, and nineteen rheumatology prognostic studies were reappraised in 2025 with GPT-Reviewer against adjudicated human QUIPS ratings using weighted kappa.

Impact 30%63
Evidence 25%95
Scale 20%35
Confidence 15%87
Recency 10%89

Updated Jul 20, 2026 · TRV-2026-0308

72
GainClimate· Stable· Evidence: Moderate (1 source)

AI-based automation in Industry 4.0/5.0 reduces energy consumption and waste on production lines by optimizing processes and minimizing downtime.

By March 2026, this peer-reviewed overview described how AI-based automation in Industry 4.0 optimized production, logistics, and resource management to reduce waste and energy use, and how Industry 5.0 expanded that with human-machine collaboration, generative AI, digital twins, and decentralized smart grids and microgrids.

Impact 30%49
Evidence 25%95
Scale 20%60
Confidence 15%87
Recency 10%89

Updated Jul 19, 2026 · TRV-2026-0281

72
GainHealth· Stable· Evidence: Moderate (1 source)

A six-protein plasma signature tested with SVM distinguished fibrotic hypersensitivity pneumonitis from idiopathic pulmonary fibrosis on an independent test set with 71.4% accuracy, offering a non-invasive diagnostic aid.

Between July 2018 and June 2022, investigators enrolled 119 subjects across healthy controls, non-fibrotic HP, fibrotic HP, and IPF cohorts and performed plasma proteomic profiling with WGCNA. They identified 813 proteins, noted enrichment of glycolysis/gluconeogenesis and pyruvate metabolism in FHP, and distilled nine differential proteins to a six-protein signature that was used to train seven machine learning classifiers.

Impact 30%63
Evidence 25%95
Scale 20%35
Confidence 15%87
Recency 10%89

Updated Jul 19, 2026 · TRV-2026-0264

AI problems · 631

68
ProblemHealth· Newly added· Evidence: Moderate (1 source)

A strategic pathway for the ethical development of AI tools in dementia care: Because responsible progress requires both safety and timely innovation, ethical evaluation must balance the risks of premature deployment against those of harmful delay.

Artificial intelligence (AI) is rapidly entering dementia clinical practice, offering opportunities across the care continuum. However, cognitive decline creates a unique ethical challenge.

Impact 30%49
Evidence 25%95
Scale 20%35
Confidence 15%87
Recency 10%97

Updated Sep 2, 2026 · TRV-2026-0963

68
ProblemLifestyle· Newly added· Evidence: Moderate (1 source)

Portable Raman spectroscopy coupled with machine learning for rapid identification and source apportionment of plastic particles in aquaculture wastewater: MPs readily adsorb heavy metals and organic pollutants to form composite contamination and accumulate through food chains, imposing ecological and human health risks.

Aquaculture expansion has exacerbated microplastics (MPs) contamination in aquaculture water bodies. MPs readily adsorb heavy metals and organic pollutants to form composite contamination and accumulate through food chains, imposing ecological and human health risks.

Impact 30%49
Evidence 25%95
Scale 20%35
Confidence 15%87
Recency 10%97

Updated Sep 2, 2026 · TRV-2026-0961

68
ProblemHealth· Stable· Evidence: Moderate (1 source)

Among Medicare beneficiaries with cancer, enrollment in stand-alone Prescription Drug Plans versus integrated Medicare Advantage Prescription Drug plans remained associated with significantly higher Medicare and beneficiary out-of-pocket spending after AI-enabled causal adjustment.

Using Medicare Current Beneficiary Survey data linked to claims from 2019 to 2022, researchers studied 3,140 cancer patients aged 65 and older representing 22.2 million beneficiaries to estimate the causal effect of stand-alone Prescription Drug Plans versus integrated Medicare Advantage Prescription Drug plans. They compared conventional regression, two-stage residual inclusion instrumental variables, and an AI-enabled Doubly Robust Machine Learning IV approach using county-level PDP penetration and white-collar worker percentage as instruments.

Impact 30%49
Evidence 25%95
Scale 20%35
Confidence 15%87
Recency 10%97

Updated Sep 1, 2026 · TRV-2026-0958

68
ProblemHealth· Stable· Evidence: Moderate (1 source)

Use of AI to automate prior authorization raises concerns about transparency, bias, and overreliance, with payer-deployed systems potentially denying claims without adequate clinical review.

Published September 1, 2026 in Journal of Managed Care & Specialty Pharmacy, this viewpoint proposes a pharmacist-overseen, AI-enabled prior authorization model for provider organizations and health systems. It outlines a conceptual workflow where AI automates routine data extraction and submissions and routes complex cases to pharmacists for clinical verification.

Impact 30%49
Evidence 25%95
Scale 20%35
Confidence 15%87
Recency 10%97

Updated Sep 1, 2026 · TRV-2026-0956

Recomputed live from the record · Sep 16, 2026, 12:21 AM